Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus, Obese
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
ISIS-PTP1BRx
Placebo
daily OAD (metformin and/or sulfonylurea)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, T2DM
Eligibility Criteria
Inclusion Criteria:
- Body mass index (BMI) >/= 27 kg/m2
- HbA1c between 7.5% and 10.5% (inclusive)
- C-Peptide (fasting) greater than or equal to 500 pmol/L
- On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for >/= 3 months prior to screening, and remain on stable dose throughout the study
- Agree to conduct home-based (fasted) blood glucose testing as directed
Exclusion Criteria:
- Clinically significant abnormalities in medical history or physical exam
- Serum creatinine > ULN at Screening
- Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST > 1.5x ULN at Screening
- History of renal transplantation or renal dialysis
- GFR < 60 mL/min at Screening
- History of diabetic ketoacidosis
- History of greater than 3 episodes of severe hypoglycemia within 6 months of screening
- Allergy to sulfur containing drugs
- Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines
- Any other significant illness or condition that may interfere with the patient participating or completing the study
- Inability or unwillingness to comply with protocol or study procedures
Sites / Locations
- Isis Investigative Site
- Isis Investigative Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigative Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
- Isis Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
ISIS-PTP1BRx
Placebo
Arm Description
Weekly Dosing for 26 Weeks
Weekly Dosing for 26 Weeks
Outcomes
Primary Outcome Measures
Incidence, severity, dose-relationship of adverse effects, and changes in laboratory evaluations as a measure of safety
Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy
Secondary Outcome Measures
Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy
Full Information
NCT ID
NCT01918865
First Posted
August 5, 2013
Last Updated
February 27, 2015
Sponsor
Ionis Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01918865
Brief Title
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
Official Title
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
February 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ionis Pharmaceuticals, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Obese
Keywords
Type 2 Diabetes Mellitus, T2DM
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
92 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ISIS-PTP1BRx
Arm Type
Experimental
Arm Description
Weekly Dosing for 26 Weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Weekly Dosing for 26 Weeks
Intervention Type
Drug
Intervention Name(s)
ISIS-PTP1BRx
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Type
Drug
Intervention Name(s)
daily OAD (metformin and/or sulfonylurea)
Primary Outcome Measure Information:
Title
Incidence, severity, dose-relationship of adverse effects, and changes in laboratory evaluations as a measure of safety
Time Frame
38 weeks
Title
Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy
Time Frame
27 weeks
Secondary Outcome Measure Information:
Title
Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy
Time Frame
27 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Body mass index (BMI) >/= 27 kg/m2
HbA1c between 7.5% and 10.5% (inclusive)
C-Peptide (fasting) greater than or equal to 500 pmol/L
On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for >/= 3 months prior to screening, and remain on stable dose throughout the study
Agree to conduct home-based (fasted) blood glucose testing as directed
Exclusion Criteria:
Clinically significant abnormalities in medical history or physical exam
Serum creatinine > ULN at Screening
Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST > 1.5x ULN at Screening
History of renal transplantation or renal dialysis
GFR < 60 mL/min at Screening
History of diabetic ketoacidosis
History of greater than 3 episodes of severe hypoglycemia within 6 months of screening
Allergy to sulfur containing drugs
Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines
Any other significant illness or condition that may interfere with the patient participating or completing the study
Inability or unwillingness to comply with protocol or study procedures
Facility Information:
Facility Name
Isis Investigative Site
City
Mar del Plata
State/Province
Buenos Aires
ZIP/Postal Code
B7600FZN
Country
Argentina
Facility Name
Isis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000CVD
Country
Argentina
Facility Name
Isis Investigational Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2E1
Country
Canada
Facility Name
Isis Investigational Site
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 3G8
Country
Canada
Facility Name
Isis Investigational Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6J 1S3
Country
Canada
Facility Name
Isis Investigational Site
City
Etobicoke
State/Province
Ontario
ZIP/Postal Code
M9R 4E1
Country
Canada
Facility Name
Isis Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4G 3E8
Country
Canada
Facility Name
Isis Investigative Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9V 4B4
Country
Canada
Facility Name
Isis Investigational Site
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7K 3H3
Country
Canada
Facility Name
Isis Investigational Site
City
Centurion
State/Province
Gauteng
ZIP/Postal Code
0154
Country
South Africa
Facility Name
Isis Investigational Site
City
Mamelodi
State/Province
Gauteng
ZIP/Postal Code
0122
Country
South Africa
Facility Name
Isis Investigational Site
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0001
Country
South Africa
Facility Name
Isis Investigational Site
City
Port Elizabeth
State/Province
Korsten
Country
South Africa
Facility Name
Isis Investigational Site
City
Durban
State/Province
KwaZulu-Natal
Country
South Africa
Facility Name
Isis Investigational Site
City
Middelburg
State/Province
Mpumalanga
Country
South Africa
Facility Name
Isis Investigational Site
City
Limpopo
State/Province
Thabazimbi
ZIP/Postal Code
0380
Country
South Africa
Facility Name
Isis Investigational Site
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7570
Country
South Africa
Facility Name
Isis Investigational Site
City
Cape Town
State/Province
Western Cape
Country
South Africa
Facility Name
Isis Investigational Site
City
Benoni
ZIP/Postal Code
1500
Country
South Africa
Facility Name
Isis Investigational Site
City
Bloemfontein
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Isis Investigational Site
City
Pretoria
ZIP/Postal Code
0184
Country
South Africa
12. IPD Sharing Statement
Citations:
PubMed Identifier
29439147
Citation
Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes. Diabetes Care. 2018 Apr;41(4):807-814. doi: 10.2337/dc17-2132. Epub 2018 Feb 9.
Results Reference
derived
Learn more about this trial
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
We'll reach out to this number within 24 hrs